Evidence map›Paper›PMID 20304997›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2010

Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity.

Lawrence S Argetsinger, Jeanne A Stuckey, Scott A Robertson, Rositsa I Koleva, Joel M Cline, Jarrod A Marto, Martin G Myers, Christin Carter-Su

Abstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. History and future of leptin: Discovery, regulation and signaling.Metabolism: clinical and experimental · 2024
    Review
  4. Review
  5. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Structure, production and signaling of leptin.Metabolism: clinical and experimental · 2015
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lawrence S ArgetsingerDepartment of Molecular and Integrative Physiology, The University of Michigan Medical School, Ann Arbor, Michigan 48109-5622, USA.
Jeanne A Stuckey
Scott A Robertson
Rositsa I Koleva
Joel M Cline
Jarrod A Marto
Martin G Myers
Christin Carter-Su
University of Michigan–Ann Arbor · USDana-Farber Cancer Institute · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
PUBLIC HEALTH DEMONSTRATIONP60DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MYERS, MARTIN G · 1985 to 2012
$26.5M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
MOLECULAR DETERMINANTS OF LEPTIN RECEPTOR/JAK2 SIGNALINGR01DK056731 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MYERS, MARTIN G · 1999 to 2025
$6.0M
Growth Hormone Receptors and ActionsR37DK034171 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARTER-SU, CHRISTIN · 2001 to 2010
$3.8M
Molecular Mechanisms of Leptin Receptor/Jak2 ActionR37DK056731 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MYERS, MARTIN G · 2008 to 2017
$3.5M
UNIVERSITY OF MICHIGAN MULTIPURPOSE ARTHRITIS CENTERP60AR020557 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GOLDSTEIN, STEVEN · 1986 to 2001
$2.9M
GROWTH HORMONE RECEPTORS AND ACTIONSR01DK034171 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARTER-SU, CHRISTIN · 1986 to 2000
$256k
NCI NIH HHS P30 CA046592NCI NIH HHS P30 CA46592NIAMS NIH HHS P60-AR20557NIDDK NIH HHS DK34171NIDDK NIH HHS DK56731NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P60 DK020572NIDDK NIH HHS P60-DK20572NIDDK NIH HHS R01 DK034171NIDDK NIH HHS R01 DK056731NIDDK NIH HHS R37 DK034171NIDDK NIH HHS R37 DK056731
6 · The paper itself

Abstract

Janus kinase 2 (JAK2) is activated by a majority of cytokine family receptors including receptors for GH, leptin, and erythropoietin. To identify novel JAK2-regulatory and/or -binding sites, we set out to identify autophosphorylation sites in the kinase domain of JAK2. Two-dimensional phosphopeptide mapping of in vitro autophosphorylated JAK2 identified tyrosines 868, 966, and 972 as sites of autophosphorylation. Phosphorylated tyrosines 868 and 972 were also identified by mass spectrometry analysis of JAK2 activated by an erythropoietin-bound chimeric erythropoietin receptor/leptin receptor. Phosphospecific antibodies suggest that the phosphorylation of all three tyrosines increases in response to GH. Compared with wild-type JAK2, which is constitutively active when overexpressed, JAK2 lacking tyrosine 868, 966, or 972 has substantially reduced activity. Coexpression with GH receptor and protein tyrosine phosphatase1B allowed us to investigate GH-dependent activation of these mutated JAK2s in human embryonic kidney 293T cells. All three mutated JAK2s are activated by GH, although to a lesser extent than wild-type JAK2. The three mutated JAK2s also mediate GH activation of signal transducer and activator of transcription 3 (Stat3), signal transducer and activator of transcription 5b (Stat5b) and ERK1, but at reduced levels. Coexpression with Src-homology 2B1beta (SH2B1beta), like coexpression with GH-bound GH receptor, partially restores the activity of all three JAK2 mutants. Based on these results and the crystal structure of the JAK2 kinase domain, we hypothesize that small changes in the conformation of the regions of JAK2 surrounding tyrosines 868, 966, and 972 due to e.g. phosphorylation, binding to a ligand-bound cytokine receptor, and/or binding to Src-homology 2B1, may be essential for JAK2 to assume a maximally active conformation.

Indexed as

AnimalsBlotting, WesternCell LineGrowth HormoneHumansImmunoprecipitationJanus Kinase 2MiceMutagenesis, Site-DirectedPhosphopeptidesPhosphorylationProtein BindingProtein Structure, SecondaryProtein Structure, TertiaryRatsSignal TransductionGrowth HormoneJanus Kinase 2PhosphopeptidesTyrosine

Identifiers

PMID20304997
PMCPMC2870937
OpenAlexW2069553372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.